Addition of lomustine for bevacizumab-refractory recurrent glioblastoma

References

• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005;352:987–96.
   PubMed Web of Science ®Google Scholar
• Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol 2012;13:916–26.
   PubMed Web of Science ®Google Scholar
• Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13:707–15.
   PubMed Web of Science ®Google Scholar
• Weller M, Van den Bent M, Hopkins PA, Tonn JC, Stupp R, Falini R, et al. EANO guideline on the diagnosis and treatment of malignant glioma. Lancet Oncol (in press).
   Google Scholar
• Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma – are we there yet? Neuro Oncol 2013;15:4–27.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733–40.
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740–5.
   PubMed Web of Science ®Google Scholar
• Lassen U, Sorensen M, Gaziel TB, Hasselbalch B, Poulsen HS. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res 2013;33:1657–60.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, et al. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 2011;103:371–9.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 2011;117:5351–8.
   PubMed Web of Science ®Google Scholar
• Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 2009;11:550–5.
   PubMed Web of Science ®Google Scholar
• Taal W, Oosterkamp HM, Walenkamp AME, Beerepoot LV, Hanse M, Buter J, et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. ASCO Meeting Abstracts 2013;31:2001.
   Google Scholar
• Roth P, Regli L, Tonder M, Weller M. Tumor-associated edema in brain cancer patients: Pathogenesis and management. Expert Rev Anticancer Ther 2013;13:1319–25.
   PubMed Web of Science ®Google Scholar
• Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. Expert Rev Anticancer Ther 2010;28:1168–74.
   Google Scholar
• Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013;31:3212–8.
   PubMed Web of Science ®Google Scholar
• Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 2011;76:87–93.
   PubMed Web of Science ®Google Scholar
• Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, et al. Concerns about anti- angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009;9:444.
   PubMed Web of Science ®Google Scholar
• Claes A, Wesseling P, Jeuken J, Maass C, Heerschap A, Leenders WP. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Therapeut 2008;7:71–8.
   PubMed Web of Science ®Google Scholar
• Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012;21:82–91.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Herndon JE, 2nd, Peters KB, Desjardins A, Coan A, Lou E, et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer 2012;107:1481–7.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Herndon JE, 2nd, Peters K, Desjardins A, Coan A, Lou E, et al. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol 2012;107:213–21.
   PubMed Web of Science ®Google Scholar
• Wiestler B, Radbruch A, Osswald M, Combs SE, Jungk C, Winkler F, et al. Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. J Neurooncol 2014;117:85–92.
   PubMed Web of Science ®Google Scholar